Parameter
| Biomarker | FLT4 (VEGFR3) | Full name | Fms-related tyrosine kinase 4 (vascular endothelial growth factor receptor 3) | Molecular Type | Nucleic acid (DNA)/protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | 195 kDa | Core Functional Dimensions | Prognosis and therapeutic targets | |
| Disease | Angiosarcoma | Disease Subtypes | / | ||
| Organ | Vascular/lymphatic endothelial cells, tumor cells | Test Sample / Technology Platform | Organization (NGS, FISH, IHC, WES) | ||
| Pathobiological Mechanisms | Gene amplification or expression, regulation lymph angiogenesis and tumor metastasis | ||||
| Clinical Availability Status | Clinical validation: secondary common subtype | ||||
| Notes and Dynamics | With MYC amplification (secondary AS), amplification is associated with poor prognosis, sensitive to sorafenib etc TKIs | ||||